Value of serum miR-486-5p combined with carbohydrate antigen 19-9 in predicting resectable or borderline resectable pancreatic cancer

Yi ZHANG; Weiwei ZHANG; Fangyu XIE; Wenli LI; Dalei JIANG; Xiaojuan JIA; Lailin FU; Yao WANG; Bin CHEN; Min SONG; Lisha JI; Xiangjun XIE

doi:10.3969/j.issn.1001-5256.2021.10.028

Volume 37 Issue 10

Oct. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(10): 2400-2404

PDF( 2657 KB)

Value of serum miR-486-5p combined with carbohydrate antigen 19-9 in predicting resectable or borderline resectable pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2021.10.028

Yi ZHANG^{1a, 2},
Weiwei ZHANG^1a,
Fangyu XIE^1b,
Wenli LI^1a,
Dalei JIANG^1a,
Xiaojuan JIA^1a,
Lailin FU^1a,
Yao WANG^1a,
Bin CHEN^1c,
Min SONG^1d,
Lisha JI^1d,
Xiangjun XIE^{1a
,
,}

1a.
Department of Gastroenterology, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao, Shandong 266011, China
1b.
Department of Cardiology, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao, Shandong 266011, China
1c.
Department of Hepatobiliary Surgery, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao, Shandong 266011, China
1d.
Endoscope Center, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao, Shandong 266011, China
2.
Dalian Medical University, Dalian, Liaoning 116044, China

Research funding:

People's Livelihood Science and Technology Project of Qingdao (19-6-1-22-nsh)

Received Date: 2021-02-22
Accepted Date: 2021-04-06
Published Date: 2021-10-20

Abstract

Abstract

Objective To investigate the expression level of serum miR-486-5p in patients with pancreatic cancer and the value of serum miR-486-5p combined with carbohydrate antigen 19-9 (CA19-9) in predicting the resectability of pancreatic cancer. Methods A total of 60 patients who were diagnosed with pancreatic cancer in Qingdao Municipal Hospital from September 2018 to December 2020 were enrolled, among whom 32 patients had resectable or borderline resectable pancreatic cancer (operable group) and 28 had unresectable pancreatic cancer (non-operable group), and a benign pancreatic disease group with 30 patients and a healthy control group with 44 individuals were also established. Quantitative real-time PCR was used to measure the serum level of miR-486-5p in each group, and the relative expression level of miR-486-5p was calculated to analyze its association with the clinical features of pancreatic cancer, including age, sex, tumor location, tumor size, TNM stage, lymphatic metastasis, and distant metastasis. The Mann-Whitney U test was used for comparison of non-normally distributed continuous variables between two groups, and the chi-square test was used for comparison of categorical variables. The receiver operating characteristic (ROC) curve was plotted, and a binary logistic regression analysis was used to calculate the combined predictive value and then investigate the value of serum miR-486-5p combined with CA19-9 in predicting the resectability of pancreatic cancer. Results The relative expression level of serum miR-486-5p in the operable group [2.16 (1.38~3.30)] and the non-operable group [4.65 (2.80~9.90)] was significantly higher than that in the benign pancreatic disease group [1.01 (0.52~1.53)] and the healthy control group [0.99 (0.24~1.01)] (all P < 0.001). There were significant differences in the number of patients with low or high expression of miR-486-5p between the patients with different TNM stages, presence or absence of lymphatic metastasis, and presence or absence of distant metastasis (χ²=13.765, 5.157, and 6.638, all P < 0.05). Compared with CA19-9 alone, miR-486-5p+CA19-9 had a significantly better value in distinguishing the operable group from the benign pancreatic disease group (area under the ROC curve [AUC]=0.87, 95% confidence interval [CI]: 0.760-0.942; with a sensitivity of 81.3% and a specificity of 83.3%), distinguishing the operable group from the healthy control group (AUC=0.92, 95% CI: 0.836-0.970; with a sensitivity of 90.6% and a specificity of 86.4%), and distinguishing the operable group from the non-operable group (AUC=0.94, 95%CI: 0.884-0.998; with a sensitivity of 85.7% and a specificity of 93.7%) (Z=2.841, 2.510, and 2.387, all P < 0.05), and the optimal cut-off values were 3.12, 3.21, and 6.63, respectively. Conclusion MiR-486-5p can be used as a serum biomarker for the diagnosis of pancreatic cancer, and miR-486-5p combined with CA19-9 has a better clinical value than CA19-9 alone in predicting the resectability of pancreatic cancer in the patients with benign pancreatic diseases and the healthy population.
- Pancreatic Neoplasms,
- MicroRNAs,
- CA-19-9 Antigen

FullText(HTML)

References(23)

References

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322 /caac.21492.
[2]	VENKATESAN P. Biomarkers for subtypes of pancreatic ductal adenocarcinoma[J]. Lancet Oncol, 2017, 18(12): e718. DOI: 10.1016 /S1470-2045(17)30842-2.
[3]	ZHOU J, QIE S, FANG H, et al. MiR-487a-3p suppresses the malignant development of pancreatic cancer by targeting SMAD7[J]. Exp Mol Pathol, 2020, 116: 104489. DOI: 10.1016 /j.yexmp.2020.104489.
[4]	SPRINGETT GM, HOFFE SE. Borderline resectable pancreatic cancer: On the edge of survival[J]. Cancer Control, 2008, 15(4): 295-307. DOI: 10.1177 /107327480801500404.
[5]	BLOOMSTON M, FRANKEL WL, PETROCCA F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis[J]. JAMA, 2007, 297(17): 1901-1908. DOI: 10.1001/jama.297.17.1901.
[6]	NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma(Version 1.2020)[EB/OL]. NCCN 2020[2019-11-26]. http://www.nccn.org.
[7]	GABLO NA, PROCHAZKA V, KALA Z, et al. Cell-free microRNAs as non-invasive diagnostic and prognostic bio- markers in pancreatic cancer[J]. Curr Genomics, 2019, 20(8): 569-580. DOI: 10.2174/1389202921666191217095017.
[8]	SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. DOI: 10.3322/caac.21551.
[9]	USHIDA Y, INOUE Y, ITO H, et al. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment[J]. Pancreatology, 2021, 21(1): 130-137. DOI: 10.1016/j.pan.2020.11.026.
[10]	CHANG JC, KUNDRANDA M. Novel diagnostic and predictive biomarkers in pancreatic adenocarcinoma[J]. Int J Mol Sci, 2017, 18(3): 667. DOI: 10.3390/ijms18030667.
[11]	MIZRAHI JD, SURANA R, VALLE JW, et al. Pancreatic cancer[J]. Lancet, 2020, 395(10242): 2008-2020. DOI: 10.1016/s0140-6736(20)30974-0.
[12]	PORUK KE, GAY DZ, BROWN K, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: Diagnostic and prognostic updates[J]. Curr Mol Med, 2013, 13(3): 340-351. DOI: 10.2174/1566524011313030003.
[13]	MAHER TM, OBALLA E, SIMPSON JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: An analysis from the multicentre PROFILE cohort study[J]. Lancet Respir Med, 2017, 5(12): 946-955. DOI: 10.1016/S2213-2600(17)30430-7.
[14]	BARTEL DP. MicroRNAs: Genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-297. DOI: 10.1016/s0092-8674(04)00045-5.
[15]	GARZON R, CALIN GA, CROCE CM. MicroRNAs in cancer[J]. Annu Rev Med, 2009, 60: 167-179. DOI: 10.1146/annurev.med.59.053006.104707.
[16]	HUMMEL R, HUSSEY DJ, HAIER J. MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in different tumour types[J]. Eur J Cancer, 2010, 46(2): 298-311. DOI: 10.1016/j.ejca.2009.10.027.
[17]	LANG B, ZHAO S. miR-486 functions as a tumor suppressor in esophageal cancer by targeting CDK4/BCAS2[J]. Oncol Rep, 2018, 39(1): 71-80. DOI: 10.3892/or.2017.6064.
[18]	XU J, CAO Z, LIU W, et al. Plasma miRNAs effectively distinguish patients with pancreatic cancer from controls: A multicenter study[J]. Ann Surg, 2016, 263(6): 1173-1179. DOI: 10.1097/SLA.0000000000001345.
[19]	WANG W, LIU B, SUN S, et al. Downregulation of miR-486-5p enhances the anti-tumor effect of 5-fluorouracil on pancreatic cancer cells[J]. Onco Targets Ther, 2020, 13: 1649-1659. DOI: 10.2147/OTT.S231153.
[20]	YANG Q, WANG S, HUANG J, et al. Serum miR-20a and miR-486 are potential biomarkers for discriminating colorectal neoplasia: A pilot study[J]. J Cancer Res Ther, 2018, 14(7): 1572-1577. DOI: 10.4103/jcrt.JCRT_1198_16.
[21]	SUN H, CUI C, XIAO F, et al. miR-486 regulates metastasis and chemosensitivity in hepatocellular carcinoma by targeting CLDN10 and CITRON[J]. Hepatol Res, 2015, 45(13): 1312-1322. DOI: 10.1111/hepr.12500.
[22]	MEES ST, MARDIN WA, SIELKER S, et al. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas[J]. Ann Surg Oncol, 2009, 16(8): 2339-2350. DOI: 10.1245/s10434-009-0531-4.
[23]	WANG Y, ZHENG D, TAN Q, et al. Nanopore-based detection of circulating microRNAs in lung cancer patients[J]. Nat Nanotechnol, 2011, 6(10): 668-674. DOI: 10.1038/nnano.2011.147.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (335) PDF downloads(20)

Value of serum miR-486-5p combined with carbohydrate antigen 19-9 in predicting resectable or borderline resectable pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2021.10.028

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Value of serum miR-486-5p combined with carbohydrate antigen 19-9 in predicting resectable or borderline resectable pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2021.10.028

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content